MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.00
-0.41 (-1.55%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.41
Open26.25
Bid25.11 x 900
Ask27.24 x 1000
Day's Range25.68 - 26.52
52 Week Range25.68 - 50.44
Volume1,765,357
Avg. Volume884,312
Market Cap1.908B
Beta (3Y Monthly)1.08
PE Ratio (TTM)92.53
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?
    Motley Fool5 days ago

    Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad?

    The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Myriad Genetics Inc.

    Myriad Genetics Inc NASDAQ/NGS:MYGNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining Bearish sentimentShort interest | NeutralShort interest is moderately high for MYGN with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 9. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MYGN are favorable, with net inflows of $2.94 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of MYGN earnings conference call or presentation 7-May-19 8:30pm GMT

    Q3 2019 Myriad Genetics Inc Earnings Call

  • Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today
    Motley Fool11 days ago

    Why Marathon Petroleum, Livent, and Myriad Genetics Slumped Today

    These stocks struggled on a mixed day on Wall Street.

  • Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript
    Motley Fool12 days ago

    Myriad Genetics Inc (MYGN) Q3 2019 Earnings Call Transcript

    MYGN earnings call for the period ending March 31, 2019.

  • Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
    Zacks12 days ago

    Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

    Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

  • Myriad Genetics (MYGN) Beats Q3 Earnings Estimates
    Zacks12 days ago

    Myriad Genetics (MYGN) Beats Q3 Earnings Estimates

    Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press12 days ago

    Myriad: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Salt Lake City-based company said it had profit of 9 cents. Earnings, adjusted for one-time gains and costs, came to 46 cents per share. The results topped Wall Street expectations. ...

  • Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
    Zacks20 days ago

    Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

    Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Here’s What Hedge Funds Think About Myriad Genetics, Inc. (MYGN)
    Insider Monkey20 days ago

    Here’s What Hedge Funds Think About Myriad Genetics, Inc. (MYGN)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • 3 Medical Product Stocks Set to Beat This Earnings Season
    Zacks27 days ago

    3 Medical Product Stocks Set to Beat This Earnings Season

    The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

  • Top Gene-Sequencing Stocks for 2019
    Motley Foollast month

    Top Gene-Sequencing Stocks for 2019

    These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

  • Why Myriad Genetics, Inc. (NASDAQ:MYGN) Is A Financially Healthy Company
    Simply Wall St.last month

    Why Myriad Genetics, Inc. (NASDAQ:MYGN) Is A Financially Healthy Company

    Mid-caps stocks, like Myriad Genetics, Inc. (NASDAQ:MYGN) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Despite this...

  • Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck
    Zackslast month

    Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck

    The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.

  • Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake
    Zacks2 months ago

    Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake

    The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.

  • Myriad Genetics Gains on Innovation, New Reimbursements
    Zacks2 months ago

    Myriad Genetics Gains on Innovation, New Reimbursements

    Myriad Genetics (MYGN) aims at raising revenues by commercializing its product suite that includes Vectra DA, Prolaris, myPath Melanoma, Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test.

  • Myriad's myPath Melanoma Test Awarded Medicare Coverage
    Zacks2 months ago

    Myriad's myPath Melanoma Test Awarded Medicare Coverage

    The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.

  • Some Myriad Genetics (NASDAQ:MYGN) Shareholders Are Down 19%
    Simply Wall St.2 months ago

    Some Myriad Genetics (NASDAQ:MYGN) Shareholders Are Down 19%

    Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the marketRead More...

  • Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February
    Motley Fool2 months ago

    Here's Why Genetic Testing Stocks Rose as Much as 42.9% in February

    Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.

  • Why Is Myriad (MYGN) Down 0.5% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Myriad (MYGN) Down 0.5% Since Last Earnings Report?

    Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.